Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

NICE recommends two new treatments for inflammatory arthritis

June 18, 2021
Medical Communications Eli Lilly, NICE, Novartis

NICE has recommended two new treatments for axial spondyloarthritis, an underdiagnosed and debilitating type of inflammatory arthritis. Ixekizumab (also known …

News

Novartis report longest median OS in breast cancer study

June 3, 2021
Novartis, breast cancer, trials

Novartis has announced updated median overall survival (OS) results for Kisqali (ribociclib), in combination with fulvestrant, in postmenopausal women with …

News

Novartis eye treatment for diabetics shows positive results in Phase III trial

May 4, 2021
Manufacturing and Production DME, Novartis, diabetic macular edema, macular edema, pharma, pharma news

Novartis’ Beovu treatment for diabetic macular edema (DME) – an eye condition that can cause blindness – has shown positive …

News

Novartis multiple sclerosis treatment recommended by NICE

April 20, 2021
Manufacturing and Production NICE, Novartis, multiple sclerosis, pharma, pharma news

NICE have recommenced Novartis’ ofatumumab (Kesimpta) for the treatment of relapsing remitting MS (RRMS) in adult patients for use on …

News

Novartis signs capacity and technology transfer agreement for Roche drug

April 15, 2021
Novartis, Roche, production

Novartis has signed an initial agreement with Roche to reserve capacity and implement the technology transfer for the production of …

News

Novartis MS therapy gains MHRA and EC approval

April 8, 2021
European Commission, MHRA, Novartis, pharma, pharma news

The MHRA and European Commission have both granted marketing authorisation to Novartis for its Kesimpta therapy, for the treatment of …

News

Novartis and Artios Pharma to collaborate on DDR cancer therapies

April 7, 2021
Research and Development Novartis, RLT, oncology

Novartis and Artios Pharma have announced a global research collaboration to discover and validate next generation DNA damage response (DDR) …

News

Novartis prostate cancer treatment sees positive Phase III results

March 23, 2021
Manufacturing and Production Novartis, oncology

Novartis has today announced positive results from its Phase III VISION study with 177Lu-PSMA-617, seeing significant improvements in overall survival …

News
novartis_window

Novartis’ canakinumab fails to improve lung cancer survival in Phase III study

March 9, 2021
Manufacturing and Production Cancer, Novartis, lung cancer

Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab, an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent …

News

Novartis signs agreement to manufacture CureVac’s COVID-19 vaccine

March 5, 2021
Medical Communications COVID-19, CureVac, Novartis, vaccines

CureVac and Novartis have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the …

News

Verona Pharma appoints Novartis Gene Therapies VP Lisa Deschamps to its board

March 2, 2021
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, verona, verona pharma

Verona Pharma has appointed Lisa Deschamps, Senior Vice President and Chief Business Officer of Novartis Gene Therapies, as Non-Executive Director …

Appointment

NICE recommends Novartis’ ribociclib in combination with fulvestrant for breast cancer

February 26, 2021
Medical Communications Cancer, NICE, Novartis

NICE has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior endocrine therapy. It will be made …

News

Novartis and Gates Foundation join forces on sickle cell disease research

February 17, 2021
Research and Development Novartis, sickle cell disease

Novartis has entered into a grant agreement with the Bill & Melinda Gates Foundation, under which the foundation will fund …

News

FDA approves Novartis’ heart failure drug Entresto

February 17, 2021
Research and Development FDA, Novartis

The FDA has approved Novartis’ Entresto (sacubitril/valsartan) to reduce the risk of cardiovascular death and hospitalisation for heart failure in …

News
novartis_window

CHMP recommends marketing authorisation for Novartis’ Kesimpta

February 1, 2021
Sales and Marketing Novartis, multiple sclerosis

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorisation of Novartis’ Kesimpta (ofatumumab) for …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025